Answers are grounded in this paper and cite their sources.
In silico methods identify novel PI3K inhibitors, suggesting improvements for cancer treatment.
Phosphoinositide 3‐kinase (PI3K) is a crucial target for therapeutic intervention. PI3K inhibitors have shown preliminary therapeutic efficacy and substantial potential in oncology. Copanlisib is the first pan‐PI3K inhibitor approved by the FDA, demonstrating noteworthy efficacy in patients with lymphoma. However, it is associated with considerable adverse effects and suboptimal isoform selectivity, suggesting that its selectivity and overall drug‐likeness require further optimization. In this study, we developed an integrated in silico workflow centered on copanlisib for the development of PI3K inhibitors. Initially, a 3D‐QSAR pharmacophore model was developed using copanlisib and its derivatives, with its reliability confirmed through cost analysis, Fisher's randomization, and predictive validation. Second, we benchmarked five molecular docking programs, with CDOCKER exhibiting superior pose reproduction; the classification of inhibitors significantly improved when combined with the Ludi3 scoring function. Subsequently, we created a virtual library of copanlisib derivatives based on the core structure of copanlisib utilizing a reaction‐based scaffold growth approach. Following assessments of drug‐likeness and predictions from the pharmacophore model and molecular docking, we identified several compounds with high prediction scores as potential inhibitors. The highest ranked hit was chosen for molecular dynamics simulations and binding free‐energy calculations to elucidate the binding mechanism of the novel inhibitor with PI3K.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: